/
Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Mentions
1 mention · latest on 2 Sept 2026
See which tracked investors hold Candel Therapeutics, Inc. →Ownership and position changes on OwnershipTrace
| Investing w/ MartinBlog | August Wrap Up | - | 2 Sept 2026 |